Thirty years of VRE in Germany - "expect the unexpected": The view from the National Reference Centre for Staphylococci and Enterococci.


Journal

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
ISSN: 1532-2084
Titre abrégé: Drug Resist Updat
Pays: Scotland
ID NLM: 9815369

Informations de publication

Date de publication:
12 2020
Historique:
received: 28 09 2020
revised: 12 10 2020
accepted: 15 10 2020
pubmed: 16 11 2020
medline: 28 9 2021
entrez: 15 11 2020
Statut: ppublish

Résumé

Enterococci are commensals of the intestinal tract of many animals and humans. Of the various known and still unnamed new enterococcal species, only isolates of Enterococcus faecium and Enterococcus faecalis have received increased medical and public health attention. According to textbook knowledge, the majority of infections are caused by E. faecalis. In recent decades, the number of enterococcal infections has increased, with the increase being exclusively associated with a rising number of nosocomial E. faecium infections. This increase has been accompanied by the dissemination of certain hospital-acquired strain variants and an alarming progress in the development of antibiotic resistance namely vancomycin resistance. With this review we focus on a description of the specific situation of vancomycin resistance among clinical E. faecium isolates in Germany over the past 30 years. The present review describes three VRE episodes in Germany, each of which is framed by the beginning and end of the respective decade. The first episode is specified by the first appearance of VRE in 1990 and a country-wide spread of specific vanA-type VRE strains (ST117/CT24) until the late 1990s. The second decade was initially marked by regional clusters and VRE outbreaks in hospitals in South-Western Germany in 2004 and 2005, mainly caused by vanA-type VRE of ST203. Against the background of a certain "basic level" of VRE prevalence throughout Germany, an early shift from the vanA genotype to the vanB genotype in clinical isolates already occurred at the end of the 2000s without much notice. With the beginning of the third decade in 2010, VRE rates in Germany have permanently increased, first in some federal states and soon after country-wide. Besides an increase in VRE prevalence, this decade was marked by a sharp increase in vanB-type resistance and a dominance of a few, novel strain variants like ST192 and later on ST117 (CT71, CT469) and ST80 (CT1065). The largest VRE outbreak, which involved about 2,900 patients and lasted over three years, was caused by a novel and until that time, unknown strain type of ST80/CT1013 (vanB). Across all periods, VRE outbreaks were mainly oligoclonal and strain types varied over space (hospital wards) and time. The spread of VRE strains obviously respects political borders; for instance, both vancomycin-variable enterococci which were highly prevalent in Denmark and ST796 VRE which successfully disseminated in Australia and Switzerland, were still completely absent among German hospital patients, until to date.

Identifiants

pubmed: 33189998
pii: S1368-7646(20)30062-5
doi: 10.1016/j.drup.2020.100732
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Bacterial Proteins 0
VanA ligase, Bacteria 0
VanB protein, Enterococcus 0
Carbon-Oxygen Ligases EC 6.1.-

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

100732

Investigateurs

Karsten Becker (K)
Stefan Borgmann (S)
Andreas Diefenbach (A)
Axel Hamprecht (A)
Michael Hogardt (M)
Thomas Wichelhaus (T)
Volkhard Kemp (V)
Nils-Olaf Huebner (NO)
Achim Kaasch (A)
Gernot Geginat (G)
Wolfgang Kohnen (W)
Alexander Menzer (A)
T Krause (T)
Thomas Miethke (T)
Felix Pranada (F)
Florian Radojn (F)
Steffen Tobisch (S)
Verena Jansen (V)
Thomas Regnath (T)
Uwe Bührlen (U)
Wulf Schneider-Brachert (W)
Roman Schwarz (R)
Michaela Luemen (M)
Robert Skov (R)
Alexander Thuermer (A)
Heike von Baum (HV)
Michael Weig (M)
Groß Uwe (G)
Lutz Zabel (L)
Hinrik von Wulffen (HV)
Stefanie Döring (S)

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Auteurs

Guido Werner (G)

National Reference Centre for Staphylococci and Enterococci, Division Nosocomial Pathogens and Antibiotic Resistances, Department of Infectious Diseases, Robert Koch Institute, Wernigerode Branch, Germany. Electronic address: wernerg@rki.de.

Bernd Neumann (B)

National Reference Centre for Staphylococci and Enterococci, Division Nosocomial Pathogens and Antibiotic Resistances, Department of Infectious Diseases, Robert Koch Institute, Wernigerode Branch, Germany.

Robert E Weber (RE)

National Reference Centre for Staphylococci and Enterococci, Division Nosocomial Pathogens and Antibiotic Resistances, Department of Infectious Diseases, Robert Koch Institute, Wernigerode Branch, Germany.

Michael Kresken (M)

Antiinfectives Intelligence, Rheinbach, Germany.

Constanze Wendt (C)

MVZ Labor Dr. Limbach, Heidelberg, Germany.

Jennifer K Bender (JK)

National Reference Centre for Staphylococci and Enterococci, Division Nosocomial Pathogens and Antibiotic Resistances, Department of Infectious Diseases, Robert Koch Institute, Wernigerode Branch, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH